ConductScience.org, home

Paper31392201

An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Korlimarla A and 3 others. Ann Transl Med, 2019. Cited by 66 papers, by iCite.

Cite this record

ConductScience Library. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. Papers, record 31392201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31392201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
PubMed
Journal
Ann Transl Med
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
66
iCite
Relative citation ratio, by iCite
3.13
iCite
Revised in PubMed
2020-10-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Korlimarla AAditi
2Lim JAJeong-A
3Kishnani PSPriya S
4Sun BBaodong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References91

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110513698Hydrocephalus associated with glycogen storage disease type II (Pompe's disease).Pediatr Neurol1999https://conductscience.org/library/papers/10513698PubMed
210547605Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.J Pathol1999https://conductscience.org/library/papers/10547605PubMed
31055118Generalized glycogen storage disease in sheep.J Comp Pathol1975https://conductscience.org/library/papers/1055118PubMed
410838256Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene.Neuromuscul Disord2000https://conductscience.org/library/papers/10838256PubMed
511552029Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2.Neurology2001https://conductscience.org/library/papers/11552029PubMed
612192090Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/12192090PubMed
712897283The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.Pediatrics2003https://conductscience.org/library/papers/12897283PubMed
814253576POMPE'S DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE.J Neuropathol Exp Neurol1965https://conductscience.org/library/papers/14253576PubMed
915366815Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.Chang Gung Med J2004https://conductscience.org/library/papers/15366815PubMed
1016212810The role of pericytes in blood-vessel formation and maintenance.Neuro Oncol2005https://conductscience.org/library/papers/16212810PubMed
1116702877Pompe disease diagnosis and management guideline.Genet Med2006https://conductscience.org/library/papers/16702877PubMed
1216713360Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.Mol Ther2006https://conductscience.org/library/papers/16713360PubMed
1316857770Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.Pediatr Res2006https://conductscience.org/library/papers/16857770PubMed
1416987711Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.Mol Ther2006https://conductscience.org/library/papers/16987711PubMed
1517075580Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.Lab Invest2006https://conductscience.org/library/papers/17075580PubMed
1617151339Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.Neurology2007https://conductscience.org/library/papers/17151339PubMed
1717510371Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.J Histochem Cytochem2007https://conductscience.org/library/papers/17510371PubMed
1818414476Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.Mol Ther2008https://conductscience.org/library/papers/18414476PubMed
1918471801Classification of white matter lesions on magnetic resonance imaging in elderly persons.Biol Psychiatry2008https://conductscience.org/library/papers/18471801PubMed
2018648322Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.J Neuropathol Exp Neurol2008https://conductscience.org/library/papers/18648322PubMed

See all 91 referencesDownload CSV of references

Cited by49

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.

PMIDTitleJournalYearIn PapersSource
42701350Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease.Neurol Genet2026https://conductscience.org/library/papers/42701350PubMed
42074341Pompe Disease: Pathogenesis, Molecular Mechanisms, Neurological Aspects, Diagnostics and Modern Therapeutic Approaches.Int J Mol Sci2026https://conductscience.org/library/papers/42074341PubMed
41720458Mapping glycogen accumulation and treatment effect in Pompe disease with saturation transfer MRI.Transl Res2026https://conductscience.org/library/papers/41720458PubMed
41622854Longitudinal characterization of Gaac.1826dupA mice reveals the cardiac, myopathic and biochemical phenotypes of Pompe disease.Dis Model Mech2026https://conductscience.org/library/papers/41622854PubMed
41483684Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease.EBioMedicine2026https://conductscience.org/library/papers/41483684PubMed
41148004A retrospective cohort study describing the disease burden in patients with Pompe disease treated with enzyme replacement therapy in the United States.J Neuromuscul Dis2026https://conductscience.org/library/papers/41148004PubMed
40927766A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40927766PubMed
40893165Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40893165PubMed
40518673Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.Mol Ther2025https://conductscience.org/library/papers/40518673PubMed
40329530Current clinical applications of AAV-mediated gene therapy.Mol Ther2025https://conductscience.org/library/papers/40329530PubMed
40268518Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease.Clin Transl Med2025https://conductscience.org/library/papers/40268518PubMed
40183436Management of Pompe disease alongside and beyond ERT: a narrative review.Acta Myol2025https://conductscience.org/library/papers/40183436PubMed
39949979Gene therapy for genetic diseases: challenges and future directions.MedComm (2020)2025https://conductscience.org/library/papers/39949979PubMed
39859472Highlights of Precision Medicine, Genetics, Epigenetics and Artificial Intelligence in Pompe Disease.Int J Mol Sci2025https://conductscience.org/library/papers/39859472PubMed
39817232Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease.Ann Transl Med2024https://conductscience.org/library/papers/39817232PubMed
39309683Brain glycogen build-up measured by magnetic resonance spectroscopy in classic infantile Pompe disease.Brain Commun2024https://conductscience.org/library/papers/39309683PubMed
39295144Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.Mol Ther2024https://conductscience.org/library/papers/39295144PubMed
39277505Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics2024https://conductscience.org/library/papers/39277505PubMed
38948331Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.Mol Ther Nucleic Acids2024https://conductscience.org/library/papers/38948331PubMed
38248833Altered Sphingolipid Hydrolase Activities and Alpha-Synuclein Level in Late-Onset Schizophrenia.Metabolites2023https://conductscience.org/library/papers/38248833PubMed

See all 49 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GAA2548PubTator's text mininghttps://conductscience.org/library/genes/2548

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31392201

GET https://conductscience.org/api/papers/v1/31392201/references?page=2